|ACADIA Pharmaceuticals Inc.|
3911 Sorrento Valley Boulevard
United States - Map
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimers disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinsons disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
|Dr. Uli Hacksell Ph.D.,
Chief Exec. Officer, Pres and Director
|Mr. Thomas H. Aasen CPA,
Chief Financial Officer, Chief Bus. Officer, Principal Accounting Officer, Exec. VP and Treasurer
|Mr. Glenn F. Baity ,
VP, Gen. Counsel, Corp. Compliance Officer and Sec.
|Dr. Roger G. M. Mills M.D.,
Chief Medical Officer and Exec. VP of Devel.
|Ms. Lisa Barthelemy ,
Director of Investor Relations
|Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|